Cramer's Lightning Round: Sell ImmunoGen and take the gain

• It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Immunogen's year-to-date stock performance.

ImmunoGen: "Yeah, it had a good read out at the ASCO conference, we've been waiting for that cancer drug to pay off, and it actually did. Congratulations to them, but you know what? It is time to [sell! sell! sell!] and take the gain.

Ameriprise's year-to-date stock performance.

Ameriprise: "I have always liked the stock of Ameriprise, and you know what? I have them featured, and there's a particular reason, it's not a good one. I've always felt that it's a good solid but not exciting stock, and my viewers wouldn't like it. That's wrong, what matters is making money. It's making you money."

inTest's year-to-date stock performance.

inTest: "That thing is so hot. Its sizzling. I can't go there, 52-week high. I would rather take profits than buy here."

Southern Co.'s year-to-date stock performance.

Southern Co.: "Once they had finished that plan, I decided, you know what? It's ok. I think you're in good shape."

Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram

Questions, comments, suggestions for the "Mad Money" website? [e-mail]